English
简体中文
Total: £ 56.28
Published Date: 2025-01-13 | Pages: 82 | Tables: 86 | Pharma & Healthcare
The global market for Neuromyelitis Optica Drug was valued at US$ 49.8 million in the year 2024 and is projected to reach a revised size of US$ 61.1 million by 2031, growing at a CAGR of 3.0% during the forecast period.
Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren"t yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.
Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.
Europe is the largest Neuromyelitis Optica Drug market with about 40% market share. North America is follower, accounting for about 35% market share.
The key players are Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP etc. Top 3 companies occupied about 35% market share.
This report aims to provide a comprehensive presentation of the global market for Neuromyelitis Optica Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuromyelitis Optica Drug.
The Neuromyelitis Optica Drug market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neuromyelitis Optica Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neuromyelitis Optica Drug companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Fresenius
Teva
Sandoz
Intas
Gyjtrs
NANG KUANG
Tianjin Kingyork
Baxter
CSL
Grifols
Octapharma
CBOP
Segment by Type
Glucocorticoids
Immunotherapies
Others
Segment by Application
Acute Attack
Remission Prophylactic Treatment
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neuromyelitis Optica Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neuromyelitis Optica Drug Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Glucocorticoids
1.2.3 Immunotherapies
1.2.4 Others
1.3 Market by Application
1.3.1 Global Neuromyelitis Optica Drug Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Acute Attack
1.3.3 Remission Prophylactic Treatment
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neuromyelitis Optica Drug Market Perspective (2020-2031)
2.2 Global Neuromyelitis Optica Drug Growth Trends by Region
2.2.1 Global Neuromyelitis Optica Drug Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Neuromyelitis Optica Drug Historic Market Size by Region (2020-2025)
2.2.3 Neuromyelitis Optica Drug Forecasted Market Size by Region (2026-2031)
2.3 Neuromyelitis Optica Drug Market Dynamics
2.3.1 Neuromyelitis Optica Drug Industry Trends
2.3.2 Neuromyelitis Optica Drug Market Drivers
2.3.3 Neuromyelitis Optica Drug Market Challenges
2.3.4 Neuromyelitis Optica Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neuromyelitis Optica Drug Players by Revenue
3.1.1 Global Top Neuromyelitis Optica Drug Players by Revenue (2020-2025)
3.1.2 Global Neuromyelitis Optica Drug Revenue Market Share by Players (2020-2025)
3.2 Global Neuromyelitis Optica Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Neuromyelitis Optica Drug Revenue
3.4 Global Neuromyelitis Optica Drug Market Concentration Ratio
3.4.1 Global Neuromyelitis Optica Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neuromyelitis Optica Drug Revenue in 2024
3.5 Global Key Players of Neuromyelitis Optica Drug Head office and Area Served
3.6 Global Key Players of Neuromyelitis Optica Drug, Product and Application
3.7 Global Key Players of Neuromyelitis Optica Drug, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Neuromyelitis Optica Drug Breakdown Data by Type
4.1 Global Neuromyelitis Optica Drug Historic Market Size by Type (2020-2025)
4.2 Global Neuromyelitis Optica Drug Forecasted Market Size by Type (2026-2031)
5 Neuromyelitis Optica Drug Breakdown Data by Application
5.1 Global Neuromyelitis Optica Drug Historic Market Size by Application (2020-2025)
5.2 Global Neuromyelitis Optica Drug Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Neuromyelitis Optica Drug Market Size (2020-2031)
6.2 North America Neuromyelitis Optica Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Neuromyelitis Optica Drug Market Size by Country (2020-2025)
6.4 North America Neuromyelitis Optica Drug Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neuromyelitis Optica Drug Market Size (2020-2031)
7.2 Europe Neuromyelitis Optica Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Neuromyelitis Optica Drug Market Size by Country (2020-2025)
7.4 Europe Neuromyelitis Optica Drug Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neuromyelitis Optica Drug Market Size (2020-2031)
8.2 Asia-Pacific Neuromyelitis Optica Drug Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Neuromyelitis Optica Drug Market Size by Region (2020-2025)
8.4 Asia-Pacific Neuromyelitis Optica Drug Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Neuromyelitis Optica Drug Market Size (2020-2031)
9.2 Latin America Neuromyelitis Optica Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Neuromyelitis Optica Drug Market Size by Country (2020-2025)
9.4 Latin America Neuromyelitis Optica Drug Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neuromyelitis Optica Drug Market Size (2020-2031)
10.2 Middle East & Africa Neuromyelitis Optica Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (2020-2025)
10.4 Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Neuromyelitis Optica Drug Introduction
11.1.4 Pfizer Revenue in Neuromyelitis Optica Drug Business (2020-2025)
11.1.5 Pfizer Recent Development
11.2 Fresenius
11.2.1 Fresenius Company Details
11.2.2 Fresenius Business Overview
11.2.3 Fresenius Neuromyelitis Optica Drug Introduction
11.2.4 Fresenius Revenue in Neuromyelitis Optica Drug Business (2020-2025)
11.2.5 Fresenius Recent Development
11.3 Teva
11.3.1 Teva Company Details
11.3.2 Teva Business Overview
11.3.3 Teva Neuromyelitis Optica Drug Introduction
11.3.4 Teva Revenue in Neuromyelitis Optica Drug Business (2020-2025)
11.3.5 Teva Recent Development
11.4 Sandoz
11.4.1 Sandoz Company Details
11.4.2 Sandoz Business Overview
11.4.3 Sandoz Neuromyelitis Optica Drug Introduction
11.4.4 Sandoz Revenue in Neuromyelitis Optica Drug Business (2020-2025)
11.4.5 Sandoz Recent Development
11.5 Intas
11.5.1 Intas Company Details
11.5.2 Intas Business Overview
11.5.3 Intas Neuromyelitis Optica Drug Introduction
11.5.4 Intas Revenue in Neuromyelitis Optica Drug Business (2020-2025)
11.5.5 Intas Recent Development
11.6 Gyjtrs
11.6.1 Gyjtrs Company Details
11.6.2 Gyjtrs Business Overview
11.6.3 Gyjtrs Neuromyelitis Optica Drug Introduction
11.6.4 Gyjtrs Revenue in Neuromyelitis Optica Drug Business (2020-2025)
11.6.5 Gyjtrs Recent Development
11.7 NANG KUANG
11.7.1 NANG KUANG Company Details
11.7.2 NANG KUANG Business Overview
11.7.3 NANG KUANG Neuromyelitis Optica Drug Introduction
11.7.4 NANG KUANG Revenue in Neuromyelitis Optica Drug Business (2020-2025)
11.7.5 NANG KUANG Recent Development
11.8 Tianjin Kingyork
11.8.1 Tianjin Kingyork Company Details
11.8.2 Tianjin Kingyork Business Overview
11.8.3 Tianjin Kingyork Neuromyelitis Optica Drug Introduction
11.8.4 Tianjin Kingyork Revenue in Neuromyelitis Optica Drug Business (2020-2025)
11.8.5 Tianjin Kingyork Recent Development
11.9 Baxter
11.9.1 Baxter Company Details
11.9.2 Baxter Business Overview
11.9.3 Baxter Neuromyelitis Optica Drug Introduction
11.9.4 Baxter Revenue in Neuromyelitis Optica Drug Business (2020-2025)
11.9.5 Baxter Recent Development
11.10 CSL
11.10.1 CSL Company Details
11.10.2 CSL Business Overview
11.10.3 CSL Neuromyelitis Optica Drug Introduction
11.10.4 CSL Revenue in Neuromyelitis Optica Drug Business (2020-2025)
11.10.5 CSL Recent Development
11.11 Grifols
11.11.1 Grifols Company Details
11.11.2 Grifols Business Overview
11.11.3 Grifols Neuromyelitis Optica Drug Introduction
11.11.4 Grifols Revenue in Neuromyelitis Optica Drug Business (2020-2025)
11.11.5 Grifols Recent Development
11.12 Octapharma
11.12.1 Octapharma Company Details
11.12.2 Octapharma Business Overview
11.12.3 Octapharma Neuromyelitis Optica Drug Introduction
11.12.4 Octapharma Revenue in Neuromyelitis Optica Drug Business (2020-2025)
11.12.5 Octapharma Recent Development
11.13 CBOP
11.13.1 CBOP Company Details
11.13.2 CBOP Business Overview
11.13.3 CBOP Neuromyelitis Optica Drug Introduction
11.13.4 CBOP Revenue in Neuromyelitis Optica Drug Business (2020-2025)
11.13.5 CBOP Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Neuromyelitis Optica Drug Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Glucocorticoids
Table 3. Key Players of Immunotherapies
Table 4. Key Players of Others
Table 5. Global Neuromyelitis Optica Drug Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Neuromyelitis Optica Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Neuromyelitis Optica Drug Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global Neuromyelitis Optica Drug Market Share by Region (2020-2025)
Table 9. Global Neuromyelitis Optica Drug Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global Neuromyelitis Optica Drug Market Share by Region (2026-2031)
Table 11. Neuromyelitis Optica Drug Market Trends
Table 12. Neuromyelitis Optica Drug Market Drivers
Table 13. Neuromyelitis Optica Drug Market Challenges
Table 14. Neuromyelitis Optica Drug Market Restraints
Table 15. Global Neuromyelitis Optica Drug Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global Neuromyelitis Optica Drug Market Share by Players (2020-2025)
Table 17. Global Top Neuromyelitis Optica Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuromyelitis Optica Drug as of 2024)
Table 18. Ranking of Global Top Neuromyelitis Optica Drug Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by Neuromyelitis Optica Drug Revenue (CR5 and HHI) & (2020-2025)
Table 20. Global Key Players of Neuromyelitis Optica Drug, Headquarters and Area Served
Table 21. Global Key Players of Neuromyelitis Optica Drug, Product and Application
Table 22. Global Key Players of Neuromyelitis Optica Drug, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Neuromyelitis Optica Drug Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global Neuromyelitis Optica Drug Revenue Market Share by Type (2020-2025)
Table 26. Global Neuromyelitis Optica Drug Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global Neuromyelitis Optica Drug Revenue Market Share by Type (2026-2031)
Table 28. Global Neuromyelitis Optica Drug Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global Neuromyelitis Optica Drug Revenue Market Share by Application (2020-2025)
Table 30. Global Neuromyelitis Optica Drug Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global Neuromyelitis Optica Drug Revenue Market Share by Application (2026-2031)
Table 32. North America Neuromyelitis Optica Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America Neuromyelitis Optica Drug Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America Neuromyelitis Optica Drug Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe Neuromyelitis Optica Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe Neuromyelitis Optica Drug Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe Neuromyelitis Optica Drug Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific Neuromyelitis Optica Drug Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific Neuromyelitis Optica Drug Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific Neuromyelitis Optica Drug Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America Neuromyelitis Optica Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America Neuromyelitis Optica Drug Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America Neuromyelitis Optica Drug Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa Neuromyelitis Optica Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (2026-2031) & (US$ Million)
Table 47. Pfizer Company Details
Table 48. Pfizer Business Overview
Table 49. Pfizer Neuromyelitis Optica Drug Product
Table 50. Pfizer Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)
Table 51. Pfizer Recent Development
Table 52. Fresenius Company Details
Table 53. Fresenius Business Overview
Table 54. Fresenius Neuromyelitis Optica Drug Product
Table 55. Fresenius Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)
Table 56. Fresenius Recent Development
Table 57. Teva Company Details
Table 58. Teva Business Overview
Table 59. Teva Neuromyelitis Optica Drug Product
Table 60. Teva Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)
Table 61. Teva Recent Development
Table 62. Sandoz Company Details
Table 63. Sandoz Business Overview
Table 64. Sandoz Neuromyelitis Optica Drug Product
Table 65. Sandoz Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)
Table 66. Sandoz Recent Development
Table 67. Intas Company Details
Table 68. Intas Business Overview
Table 69. Intas Neuromyelitis Optica Drug Product
Table 70. Intas Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)
Table 71. Intas Recent Development
Table 72. Gyjtrs Company Details
Table 73. Gyjtrs Business Overview
Table 74. Gyjtrs Neuromyelitis Optica Drug Product
Table 75. Gyjtrs Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)
Table 76. Gyjtrs Recent Development
Table 77. NANG KUANG Company Details
Table 78. NANG KUANG Business Overview
Table 79. NANG KUANG Neuromyelitis Optica Drug Product
Table 80. NANG KUANG Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)
Table 81. NANG KUANG Recent Development
Table 82. Tianjin Kingyork Company Details
Table 83. Tianjin Kingyork Business Overview
Table 84. Tianjin Kingyork Neuromyelitis Optica Drug Product
Table 85. Tianjin Kingyork Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)
Table 86. Tianjin Kingyork Recent Development
Table 87. Baxter Company Details
Table 88. Baxter Business Overview
Table 89. Baxter Neuromyelitis Optica Drug Product
Table 90. Baxter Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)
Table 91. Baxter Recent Development
Table 92. CSL Company Details
Table 93. CSL Business Overview
Table 94. CSL Neuromyelitis Optica Drug Product
Table 95. CSL Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)
Table 96. CSL Recent Development
Table 97. Grifols Company Details
Table 98. Grifols Business Overview
Table 99. Grifols Neuromyelitis Optica Drug Product
Table 100. Grifols Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)
Table 101. Grifols Recent Development
Table 102. Octapharma Company Details
Table 103. Octapharma Business Overview
Table 104. Octapharma Neuromyelitis Optica Drug Product
Table 105. Octapharma Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)
Table 106. Octapharma Recent Development
Table 107. CBOP Company Details
Table 108. CBOP Business Overview
Table 109. CBOP Neuromyelitis Optica Drug Product
Table 110. CBOP Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)
Table 111. CBOP Recent Development
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
Table 115. Authors List of This Report
List of Figures
Figure 1. Neuromyelitis Optica Drug Picture
Figure 2. Global Neuromyelitis Optica Drug Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Neuromyelitis Optica Drug Market Share by Type: 2024 VS 2031
Figure 4. Glucocorticoids Features
Figure 5. Immunotherapies Features
Figure 6. Others Features
Figure 7. Global Neuromyelitis Optica Drug Market Size by Application (2020-2031) & (US$ Million)
Figure 8. Global Neuromyelitis Optica Drug Market Share by Application: 2024 VS 2031
Figure 9. Acute Attack Case Studies
Figure 10. Remission Prophylactic Treatment Case Studies
Figure 11. Neuromyelitis Optica Drug Report Years Considered
Figure 12. Global Neuromyelitis Optica Drug Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global Neuromyelitis Optica Drug Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Neuromyelitis Optica Drug Market Share by Region: 2024 VS 2031
Figure 15. Global Neuromyelitis Optica Drug Market Share by Players in 2024
Figure 16. Global Top Neuromyelitis Optica Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuromyelitis Optica Drug as of 2024)
Figure 17. The Top 10 and 5 Players Market Share by Neuromyelitis Optica Drug Revenue in 2024
Figure 18. North America Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 19. North America Neuromyelitis Optica Drug Market Share by Country (2020-2031)
Figure 20. United States Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Canada Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Neuromyelitis Optica Drug Market Share by Country (2020-2031)
Figure 24. Germany Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. France Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. U.K. Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Italy Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Russia Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Nordic Countries Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Neuromyelitis Optica Drug Market Share by Region (2020-2031)
Figure 32. China Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Japan Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. South Korea Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Southeast Asia Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. India Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Australia Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Neuromyelitis Optica Drug Market Share by Country (2020-2031)
Figure 40. Mexico Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Brazil Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Neuromyelitis Optica Drug Market Share by Country (2020-2031)
Figure 44. Turkey Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Saudi Arabia Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. UAE Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Pfizer Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)
Figure 48. Fresenius Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)
Figure 49. Teva Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)
Figure 50. Sandoz Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)
Figure 51. Intas Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)
Figure 52. Gyjtrs Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)
Figure 53. NANG KUANG Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)
Figure 54. Tianjin Kingyork Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)
Figure 55. Baxter Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)
Figure 56. CSL Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)
Figure 57. Grifols Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)
Figure 58. Octapharma Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)
Figure 59. CBOP Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
